找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Antibodies; Volume 2: Novel Tech G. Subramanian Book 2004 Springer Science+Business Media New York 2004 HIV.cancer.cancer therapy.cells.dev

[復(fù)制鏈接]
樓主: Intimidate
41#
發(fā)表于 2025-3-28 17:24:02 | 只看該作者
Future Prospects in Antibody Engineering and Therapy, mAb to be approved for a clinical use was a murine antibody (OKT3, or Muromomab) ., it became increasingly obvious that only mAbs with a decreased immunogenicity could be used for repeated injections in Humans. The generation of a Human Anti-Mouse Antibody (HAMA) response when murine mAbs are infus
42#
發(fā)表于 2025-3-28 21:51:43 | 只看該作者
43#
發(fā)表于 2025-3-28 23:46:26 | 只看該作者
44#
發(fā)表于 2025-3-29 05:11:25 | 只看該作者
45#
發(fā)表于 2025-3-29 08:47:50 | 只看該作者
46#
發(fā)表于 2025-3-29 12:31:22 | 只看該作者
Antibodies, a Potent Tool to Target Genes into Designated Cells and Tissues, poor effects were mainly due to generation of anti-murine Abs by the patients, hindering the efficacy of the treatment. Moreover, rodent IgG Abs injected to patients have half-life of less than 20 hrs compared to several days for human Igs.
47#
發(fā)表于 2025-3-29 15:48:55 | 只看該作者
48#
發(fā)表于 2025-3-29 21:36:34 | 只看該作者
,Gef??tumoren und Gef??mi?bildungen,sylation and measuring its biological effects have revolutionized the discipline of “glycobiology”. Thus, extremely subtle alterations in glycoproteins can now be detected, and appropriate modifications brought about which were nearly impossible 20 years ago.
49#
發(fā)表于 2025-3-30 02:16:16 | 只看該作者
Die freien Gruppen und ihre Faktorgruppen, studies has been on efficacy in clinical conditions or in animal models of human cancers, and little consideration has been given to the effects of the combination of these antibodies and radiation therapy.
50#
發(fā)表于 2025-3-30 06:19:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-31 13:03
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
朝阳县| 祁阳县| 东光县| 新竹市| 永年县| 大名县| 美姑县| 湘乡市| 常德市| 广元市| 璧山县| 乌苏市| 亚东县| 揭东县| 大余县| 紫金县| 泰宁县| 普洱| 海丰县| 高要市| 武宁县| 兴和县| 秦安县| 宾阳县| 革吉县| 新干县| 淳化县| 芦溪县| 澄迈县| 科技| 司法| 西宁市| 大安市| 拉萨市| 赤水市| 承德市| 施秉县| 十堰市| 亚东县| 定结县| 宜兴市|